GLP-1-mediated delivery of the PPAR𝛼/𝛾 dual-agonist Tesaglitazar improves obesity and glucose metabolism in mice
Carmelo Quarta(Université de Bordeaux), Timo D. Müller(Helmholtz Zentrum München), Gustav Colldén(Helmholtz Zentrum München), Aimée Bastidas-Ponce(Helmholtz Zentrum München), Diego Pérez–Tilve(University of Cincinnati Medical Center), Fanny Lalloyer(Inserm), Nathalie Hennuyer(Inserm), Alexandra Harger(University of Graz), Susanna M. Hofmann(Helmholtz Zentrum München), Felix Klingelhuber(University of East Anglia), Gandhari Maity(Helmholtz Zentrum München), Aaron Novikoff(Helmholtz Zentrum München), Brian Finan(Novo Nordisk (United States)), Daniel J. Drucker(Mount Sinai Hospital), Cristina García‐Cáceres(Helmholtz Zentrum München), Eric Baugé(Inserm), Heiko Lickert(Helmholtz Zentrum München), Perla Cota(Deutsches Diabetes-Zentrum e.V.), Bin Yang, Kerstin Stemmer(University of Cincinnati), Konxhe Kulaj(Helmholtz Zentrum München), Richard D. DiMarchi(Indiana University Bloomington), Stephan Herzig(Heidelberg University), Natalie Krahmer(Helmholtz Zentrum München), Mostafa Bakhti(Max Planck Institute of Experimental Medicine), Gerald Grandl(Helmholtz Zentrum München), Christoffer Clemmensen(University of Copenhagen), Qian Zhang(Johns Hopkins University), Matthias Tschoep(Helmholtz Zentrum München), Bard Staels(Institut Pasteur de Lille), Miguel A. Sánchez-Garrido(Instituto Maimónides de Investigación Biomédica de Córdoba)
Cited by 0
Related Papers
Cardioprotection and lifespan extension by the natural polyamine spermidine
|Nature Medicine|2016|1.1k
Anti-obesity drug discovery: advances and challenges
|Nature Reviews Drug Discovery|2021|950
The role of gut hormones in glucose homeostasis
|Journal of Clinical Investigation|2007|611
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
|Endocrine Reviews|2014|602
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
|Diabetes Care|2003|578